NCT00937638

Brief Summary

The proposed research will provide important information about the role of 2 intervention diets that provide different amounts of lean beef and meet current nutrient recommendations for the treatment of Metabolic Syndrome (MetSyn), a chronic disease that is still increasing in prevalence at alarming rates. The experimental and diet designs will enable us to evaluate lifestyle interventions for MetSyn for persons who maintain weight, lose weight and maintain their weight loss, as is currently recommended in clinical practice. Importantly, the investigators will compare a diet high in lean beef (5 oz/day) which is compositionally similar (i.e., energy and nutrients) to the modified-DASH diet, a low beef diet which has become the Gold Standard for the management of cardiovascular disease (CVD) risk factors, including MetSyn. In addition, the investigators also will evaluate a moderate-high protein diet (BOLD+) that is higher in total protein (from mixed sources including lean beef, 7oz/day) than the BOLD diet, on CVD risk factors in persons with MetSyn. A follow-up study was conducted to assess dietary compliance in a sub-sample of the population at 12-months; participants were not informed of this end-point and additional consent was obtained. Hypotheses:

  1. 1.Healthful isocaloric diets that include lean beef as the primary source of protein (BOLD diet) with average (18%; BOLD) or moderate-high (28%; BOLD+) total protein intake will show similar or greater reductions in CVD risk, respectively when compared to a modified-DASH diet.
  2. 2.A healthful weight-loss diet, including lean beef as the primary source of protein in a high-moderate protein diet (BOLD+ diet), plus regular exercise (BOLD+ + ex) will reduce body weight equal to that of a BOLD + ex and DASH + ex intervention, but may improve CV risk factors (such as BP and TG), and therefore reduce the prevalence of MetSyn more than a BOLD + ex and DASH + ex intervention.
  3. 3.The BOLD diet will be more effective than the modified-DASH diet, and the BOLD+ diet more effective than the BOLD diet in maintaining the CVD benefits attained during phases 1 and 2. Dietary adherence will be better on the BOLD and BOLD + diets compared with the modified DASH diet.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
63

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2009

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2009

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

June 18, 2009

Completed
25 days until next milestone

First Posted

Study publicly available on registry

July 13, 2009

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2011

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2012

Completed
Last Updated

August 21, 2023

Status Verified

August 1, 2023

Enrollment Period

2.5 years

First QC Date

June 18, 2009

Last Update Submit

August 16, 2023

Conditions

Keywords

Metabolic syndromeLean BeefCVD

Outcome Measures

Primary Outcomes (4)

  • Criteria for Metabolic Syndrome: central obesity (weight, waist circumference, abdominal obesity), TG, HDL-C, glucose and BP

    2 weeks

  • Criteria for Metabolic Syndrome: central obesity (weight, waist circumference, abdominal obesity), TG, HDL-C, glucose and BP

    7 weeks

  • Criteria for Metabolic Syndrome: central obesity (weight, waist circumference, abdominal obesity), TG, HDL-C, glucose and BP

    13 weeks

  • Criteria for Metabolic Syndrome: central obesity (weight, waist circumference, abdominal obesity), TG, HDL-C, glucose and BP

    24 weeks

Secondary Outcomes (14)

  • Vascular endothelial function measured by endo-PAT

    2 weeks

  • Lipids and lipoproteins

    2 weeks

  • Inflammatory markers

    2 weeks

  • Vascular endothelial function measured by endo-PAT

    7 weeks

  • Vascular endothelial function measured by endo-PAT

    13 weeks

  • +9 more secondary outcomes

Study Arms (3)

Modified-DASH Diet

EXPERIMENTAL
Dietary Supplement: Modified DASH Diet

BOLD diet

EXPERIMENTAL
Dietary Supplement: BOLD Diet

BOLD-X

EXPERIMENTAL
Dietary Supplement: BOLD-X Diet

Interventions

BOLD DietDIETARY_SUPPLEMENT

Low-fat, high fruit and vegetable diet that includes lean beef (5oz/day)

Also known as: Low fat, Step II diet
BOLD diet
BOLD-X DietDIETARY_SUPPLEMENT

Low-fat, moderate-high protein diet (BOLD+) that is higher in total protein (from mixed sources including lean beef, 7oz/day) than the BOLD diet. Also high in fruits and vegetables

Also known as: Low fat, moderate protein
BOLD-X
Modified DASH DietDIETARY_SUPPLEMENT

Low-fat, high fruit and vegetable diet which has become the Gold Standard for the management of cardiovascular disease (CVD) risk factors and metabolic syndrome

Also known as: DASH diet
Modified-DASH Diet

Eligibility Criteria

Age30 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • (BMI 27-42 kg/m2)
  • Three or more of the following risk factors (defined as having MetSyn):
  • abdominal obesity \[waist circumference \> 102 cm (40 inches) in men and \> 88 cm (35 inches) in women\],
  • elevated blood glucose \[\> 110mg/dl (6.1 mmol/L)\]
  • elevated TG \[\>150 mg/dl (1.7 mmol/L)\]
  • low HDL-C \[\<40 mg/dl (1.03 mmol/L) in men and \<50 mg/dL (1.29 mmol/l) in women\]
  • hypertension (Systolic Blood Pressure \> 130 mmHg or Diastolic Blood Pressure \> 85 mmHg)\*
  • BP medication accepted if BP stable and less than 160/100mm Hg

You may not qualify if:

  • A history of myocardial infarction, stroke, diabetes mellitus, liver disease, kidney disease, and thyroid disease (unless controlled on medication)
  • Lactation, pregnancy, or desire to become pregnant during the study
  • Intake of putative cholesterol-lowering supplements (psyllium, fish oil capsules, soy lecithin, niacin, fiber, flax, and phytoestrogens, stanol/sterol supplemented foods)
  • High alcohol consumption (≥ 14 drinks/week)
  • Participation in regular physical activity (\> 1 formal session/week)
  • Lipid or glucose lowering medication

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Penn State University

University Park, Pennsylvania, 16802, United States

Location

Related Publications (1)

  • Hill AM, Harris Jackson KA, Roussell MA, West SG, Kris-Etherton PM. Type and amount of dietary protein in the treatment of metabolic syndrome: a randomized controlled trial. Am J Clin Nutr. 2015 Oct;102(4):757-70. doi: 10.3945/ajcn.114.104026. Epub 2015 Sep 9.

MeSH Terms

Conditions

Metabolic SyndromeCardiovascular Diseases

Interventions

Diet, Fat-RestrictedDietary Approaches To Stop Hypertension

Condition Hierarchy (Ancestors)

Insulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Diet TherapyNutrition TherapyTherapeuticsDietNutritional Physiological PhenomenaDiet, Food, and NutritionPhysiological Phenomena

Study Officials

  • Penny M Kris-Etherton, PhD

    Penn State University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 18, 2009

First Posted

July 13, 2009

Study Start

February 1, 2009

Primary Completion

August 1, 2011

Study Completion

March 1, 2012

Last Updated

August 21, 2023

Record last verified: 2023-08

Locations